Alexza Pharmaceuticals Newswire

Alexza Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Alexza Pharmaceuticals.

Results 1 - 20 of 50 in Alexza Pharmaceuticals

  1. Alexza Pharmaceuticals, Inc. - Financial and Strategic SWOT Analysis ReviewRead the original story

    Monday Aug 22 | Emailwire.com

    Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. Alexza Pharmaceuticals , Inc. - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations.

    Comment?

  2. Global Epilepsy Drugs Market to Grow at a CAGR of 4.45% During 2016-2020Read the original story w/Photo

    Jul 14, 2016 | SBWire

    ... Key vendors - Eisai - GSK - Pfizer - UCB Other prominent vendors - AbbVie - Acorda Therapeutics - Alexza Pharmaceuticals - Aprecia Pharmaceuticals - Aurobindo Pharma - Biscayne Pharmaceuticals - CURx Pharmaceuticals - Dainippon Sumitomo Pharma ...

    Comment?

  3. Global Epilepsy Drugs Market 2016-2020; New Report LaunchedRead the original story w/Photo

    Jul 13, 2016 | SBWire

    ... Key vendors - Eisai - GSK - Pfizer - UCB Other prominent vendors - AbbVie - Acorda Therapeutics - Alexza Pharmaceuticals - Aprecia Pharmaceuticals - Aurobindo Pharma - Biscayne Pharmaceuticals - CURx Pharmaceuticals - Dainippon Sumitomo Pharma - ...

    Comment?

  4. Delisting Of Securities Of Alexza Pharma From The Stock MarketRead the original story

    Jul 4, 2016 | BioSpace

    /PRNewswire/ -- Alexza Pharmaceuticals, Inc. ("Alexza" or the "Company") today announced that The Nasdaq Stock Market ("Nasdaq") will delist the common stock of Alexza. Alexza's stock was suspended on and has not traded on Nasdaq since that time. ...

    Comment?

  5. Delisting of Securities of Alexza Pharmaceuticals, Inc. from The Nasdaq Stock MarketRead the original story

    Jul 1, 2016 | Freshnews

    Alexza Pharmaceuticals, Inc. today announced that The Nasdaq Stock Market will delist the common stock of Alexza. Alexza's stock was suspended on June 17, 2016 and has not traded on Nasdaq since that time.

    Comment?

  6. Delisting of Securities of Alexza Pharmaceuticals, Inc., MOKO Social...Read the original story w/Photo

    Jul 1, 2016 | GlobeNewswire

    The Nasdaq Stock Market announced today that it will delist the common stock of Alexza Pharmaceuticals, Inc. Alexza Pharmaceuticals, Inc.'s stock was suspended on June 17, 2016 and has not traded on Nasdaq since that time. Nasdaq also announced that it will delist the American depositary shares of MOKO Social Media Ltd. MOKO Social Media Ltd.'s stock was suspended on June 16, 2016 and has not traded on Nasdaq since that time.

    Comment?

  7. Insiders' Week: Pharma Companies and Coca-ColaRead the original story w/Photo

    Jun 24, 2016 | GuruFocus.com

    ... high and 21.29% above its 52-week low. On June 21, Grupo Ferrer Internacional, S, 10% owner of Alexza Pharmaceuticals Inc. ( ALXA ), bought 19,456,714 shares for 90 cents per share. Since then, the price of the stock has risen by 4.4% to 94 cents ...

    Comment?

  8. Ferrer Internacional S. Grupo Purchases 19,465,714 Shares of Alexza...Read the original story w/Photo

    Jun 24, 2016 | Daily Political

    Alexza Pharmaceuticals, Inc. major shareholder Ferrer Internacional S. Grupo purchased 19,465,714 shares of the stock in a transaction dated Tuesday, June 21st. The stock was bought at an average cost of $0.90 per share, with a total value of $17,519,142.60.

    Comment?

  9. Insider Buying: Alexza Pharmaceuticals, Inc. (ALXA) Major Shareholder ...Read the original story w/Photo

    Jun 22, 2016 | AmericanBankingNews.com

    Alexza Pharmaceuticals, Inc. major shareholder Ferrer Internacional S. Grupo acquired 19,465,714 shares of the firm's stock in a transaction dated Tuesday, June 21st. The shares were acquired at an average price of $0.90 per share, for a total transaction of $17,519,142.60.

    Comment?

  10. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    May 16, 2016 | Business Wire

    ... ISIN: XS1134219598 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 16-May-2016 TO 15-Ju... ALEXZA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Ferrer Pharma, ...

    Comment?

  11. Alexza Pharmaceuticals, Inc. (ALXA) Announces Earnings ResultsRead the original story w/Photo

    May 13, 2016 | Daily Political

    Alexza Pharmaceuticals, Inc. posted its earnings results on Wednesday. The company reported earnings per share for the quarter, Market Beat.com reports.

    Comment?

  12. Shareholder Alert: Brodsky & Smith, LLC Announces Investigation of...Read the original story w/Photo

    Jul 22, 2014 | PR Newswire

    ... & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Alexza Pharmaceuticals, Inc. ("Alexza" or "the Company") (Nasdaq- ALXA-News) for possible breaches of fiduciary duty and other violations of state law ...

    Comment?

  13. Alexza Pharmaceuticals, Inc. (ALXA) Releases Quarterly Earnings ResultsRead the original story w/Photo

    May 11, 2016 | AmericanBankingNews.com

    Alexza Pharmaceuticals, Inc. issued its quarterly earnings data on Wednesday. The company reported earnings per share for the quarter, ARN reports.

    Comment?

  14. Alexza Reports 2016 First Quarter Financial ResultsRead the original story

    May 11, 2016 | Freshnews

    Alexza Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2016. The net loss for the first quarter was $3.4 million compared to $0.4 million during the same quarter in 2015.

    Comment?

  15. Ferrer to add drug aerosol delivery tech through Alexza acquisitionRead the original story w/Photo

    May 11, 2016 | In-PharmaTechnologist.com

    Grupo Ferrer Internacional will acquire Alexza Pharmaceuticals for around $2m, adding the Staccato aerosol system to its drug delivery offerings. The deal announced yesterday sees Barcelona, Spain-headquartered Ferrer enter into a definitive agreement to buy Alexza for $0.90 per share, or roughly $2m in cash.

    Comment?

  16. 's M&A Chatter for Tuesday May 10, 2016Read the original story

    May 10, 2016 | Benzinga

    ... David Driscoll said General Mills could be a target of 3G and Kraft Heinz (NASDAQ: KHC ). The Deal : Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) and Grupo Ferrer Internacional, S.A. announced Tuesday, that they have entered into a definitive ...

    Comment?

  17. Alexza to Cancel 2016 First Quarter Financial Results Earnings CallRead the original story

    May 10, 2016 | Freshnews

    Alexza Pharmaceuticals, Inc. today announced that it intends to issue a press release reporting financial results for the first quarter of fiscal 2016, as planned, immediately following the close of market on Wednesday, May 11, 2016. However, following the announcement on May 10, 2016, of Grupo Ferrer Internacional SA's proposed acquisition of Alexza, Alexza has elected not to conduct a conference call to discuss the quarterly financial results.

    Comment?

  18. Alexza Pharmaceuticals, Inc. (ALXA) to Release Earnings on WednesdayRead the original story w/Photo

    May 10, 2016 | AmericanBankingNews.com

    Alexza Pharmaceuticals last announced its quarterly earnings data on Monday, March 28th. The company reported EPS for the quarter, beating the Thomson Reuters' consensus estimate of by $0.22.

    Comment?

  19. Alexza Pharmaceuticals to be Acquired by FerrerRead the original story

    May 10, 2016 | Freshnews

    Alexza Pharmaceuticals, Inc. and Grupo Ferrer Internacional, S.A. today announced that they have entered into a definitive agreement under which Ferrer Pharma Inc. , a wholly-owned subsidiary of Ferrer, will acquire Alexza for $0.90 per share in cash. In addition to the upfront cash payment, Alexza stockholders will be granted contingent value rights to receive cash payments in four payment categories if specified milestones are achieved following the closing.

    Comment?

  20. Bay Area's Alexza Pharma Sold in $35 Million DealRead the original story

    May 9, 2016 | BioSpace

    ... Skadden, Arps, Slate, Meagher & Flom LLP and J&A Garrigues, S.L.P. acted as legal advisors to Ferrer. Alexza Pharmaceuticals is focused on the research, development, and commercialization of novel, proprietary products for the acute treatment of ...

    Comment?